Home › Research › Biomarkers
Blood-based biomarkers for Alzheimer's disease: influence of kidney function
Gaetani L, Bellomo G, Nardi G, Toja A, Streva C, Giombetti E, Torrigiani EG, Paolini Paoletti F et al.. Alzheimer's research & therapy, 2026-02-02
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
KD was associated with higher plasma concentrations of p-Tau217, p-Tau181, Aβ42, Aβ40, and NfL, not with the Aβ42/Aβ40 ratio. Creatinine- and eGFR-based correction improved the correlation between plasma and CSF NfL. For AD classification, plasma p-Tau217 showed the highest diagnostic accuracy (AUC: 0.955, 95% CI: 0.920–0.990), with creatinine correction resulting in a numerical but not statistically significant improvement (AUC: 0.965, 95% CI 0.937–0.993), whereas a modest, not significant, increase in performance was observed for p-Tau181 after correction (AUC from 0.830, 95% CI: 0.752–0.907; to 0.862, 95% CI: 0.790–0.933). Corrected p-Tau cut-offs closely aligned with those previously reported in cohorts without KD. KD alters plasma biomarker concentrations. Correction for renal function may be particularly relevant in individuals with moderate-severe KD and may facilitate the application of established plasma biomarker cut-offs derived from cohorts without KD.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Gaetani, L., Bellomo, G., Nardi, G., Toja, A., Streva, C., Giombetti, E., et al. (2026). Blood-based biomarkers for Alzheimer's disease: influence of kidney function. Alzheimer's research & therapy. https://doi.org/10.1186/s13195-026-01970-4
Vancouver
Gaetani L, Bellomo G, Nardi G, Toja A, Streva C, Giombetti E, et al. Blood-based biomarkers for Alzheimer's disease: influence of kidney function. Alzheimer's research & therapy. 2026. doi:10.1186/s13195-026-01970-4. PMID: 41630037.
BibTeX
@article{gaetani2026-41630037,
author = {Gaetani, L. and Bellomo, G. and Nardi, G. and Toja, A. and Streva, C. and Giombetti, E. and Torrigiani, E. G. and Paolini Paoletti, F. and others},
title = {{Blood-based biomarkers for Alzheimer's disease: influence of kidney function}},
journal = {Alzheimer's research \& therapy},
year = {2026},
doi = {10.1186/s13195-026-01970-4},
pmid = {41630037},
url = {https://doi.org/10.1186/s13195-026-01970-4}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- KD was associated with higher plasma concentrations of p-Tau217, p-Tau181, Aβ42, Aβ40, and NfL, not with the Aβ42/Aβ40 ratio.
- Creatinine- and eGFR-based correction improved the correlation between plasma and CSF NfL.
- For AD classification, plasma p-Tau217 showed the highest diagnostic accuracy (AUC: 0.955, 95% CI: 0.920–0.990), with creatinine correction resulting in a numerical but not statistically significant improvement (AUC: 0.965, 95% CI 0.937–0.993), whereas a modest, not significant, increase in performance was observed for p-Tau181 after correction (AUC from 0.830, 95% CI: 0.752–0.907; to 0.862, 95% CI: 0.790–0.933).
- Corrected p-Tau cut-offs closely aligned with those previously reported in cohorts without KD.
- KD alters plasma biomarker concentrations.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Participants112
- Effect sizeAUC: 0.955; AUC: 0.965
- Evidence strengthLow
How this study scored 60/100
Published in a peer-reviewed journal. Scored zero for study design and randomized / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record and multicenter collaboration, so those were left out: it earned 35 of the 58 points we could judge it on, which is 60 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Alzheimer's research & therapy) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 2 / 4 | 112 participants |
| Effect reported | 3 / 3 | Effect reported with a statistic (interval, p-value, ratio or similar) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 41630037) |
| Free to read | 2 / 2 | Free to read |
| Points | 35 / 58 | Scored on 11 of 20 parts. We have no data for the rest, so they are left out: 35 of the 58 points we could judge it on is 60 out of 100. |
| Total | 60 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.